Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 16161

  • Showing results for cannabinoids. Search instead for cannbinoids (2 items)
1.

Urine Drug Screen Trends from 1998 through 2011 Among Emergency Department Patients Treated in a University Teaching Hospital.

Korneeva N, Cvek U, Leskova A, Hutchinson K, Callahan A, Patek G, Trutschl M, Kilgore PCSR, McGauly P, Goeders N, Arnold T.

Toxicol Commun. 2018;2(1):24-34. doi: 10.1080/24734306.2018.1468539. Epub 2018 May 16.

PMID:
30906915
2.

Dilute and shoot ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) analysis of psychoactive drugs in oral fluid.

Malaca S, Busardò FP, Gottardi M, Pichini S, Marchei E.

J Pharm Biomed Anal. 2019 Mar 16;170:63-67. doi: 10.1016/j.jpba.2019.02.039. [Epub ahead of print]

PMID:
30904741
3.

The role of time and storage conditions on the composition of hashish and marijuana samples: A four-year study.

Zamengo L, Bettin C, Badocco D, Di Marco V, Miolo G, Frison G.

Forensic Sci Int. 2019 Mar 8;298:131-137. doi: 10.1016/j.forsciint.2019.02.058. [Epub ahead of print]

PMID:
30901710
4.

Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration.

Aguareles J, Paraíso-Luna J, Palomares B, Bajo-Grañeras R, Navarrete C, Ruiz-Calvo A, García-Rincón D, García-Taboada E, Guzmán M, Muñoz E, Galve-Roperh I.

Transl Neurodegener. 2019 Mar 8;8:9. doi: 10.1186/s40035-019-0148-x. eCollection 2019.

5.

Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors.

Jesus CHA, Redivo DDB, Gasparin AT, Sotomaior BB, de Carvalho MC, Genaro K, Zuardi AW, Hallak JEC, Crippa JA, Zanoveli JM, da Cunha JM.

Brain Res. 2019 Mar 18. pii: S0006-8993(19)30153-2. doi: 10.1016/j.brainres.2019.03.014. [Epub ahead of print]

PMID:
30898678
6.

[The Clinical Toxicology Perspective on the Therapeutic Use of Cannabis and Cannabinoids].

Dinis-Oliveira RJ.

Acta Med Port. 2019 Feb 28;32(2):87-90. doi: 10.20344/amp.10896. Epub 2019 Feb 28. Portuguese. No abstract available.

7.

Sex Differences in the Behavioral and Synaptic Consequences of a Single in vivo Exposure to the Synthetic Cannabimimetic WIN55,212-2 at Puberty and Adulthood.

Borsoi M, Manduca A, Bara A, Lassalle O, Pelissier-Alicot AL, Manzoni OJ.

Front Behav Neurosci. 2019 Mar 5;13:23. doi: 10.3389/fnbeh.2019.00023. eCollection 2019.

8.

Cannabinoid-sensitive receptors in cardiac health and disease.

Puhl SL.

Biochim Biophys Acta Mol Cell Res. 2019 Mar 16. pii: S0167-4889(18)30338-0. doi: 10.1016/j.bbamcr.2019.03.009. [Epub ahead of print] Review.

PMID:
30890410
9.

Assessing the Acute Effects of Prenatal Synthetic Cannabinoid Exposure on Murine Fetal Brain Vasculature Using Optical Coherence Tomography.

Raghunathan R, Liu CH, Kouka A, Singh M, Miranda RC, Larin KV.

J Biophotonics. 2019 Mar 19:e201900050. doi: 10.1002/jbio.201900050. [Epub ahead of print]

PMID:
30887665
10.

New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites.

Diao X, Huestis MA.

Front Chem. 2019 Mar 4;7:109. doi: 10.3389/fchem.2019.00109. eCollection 2019. Review.

11.

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies.

Akgün K, Essner U, Seydel C, Ziemssen T.

J Cent Nerv Syst Dis. 2019 Mar 11;11:1179573519831997. doi: 10.1177/1179573519831997. eCollection 2019. Review.

12.

Cannabinoids stimulate the TRP-channel dependent release of both serotonin and dopamine to modulate behavior in C. elegans.

Oakes M, Law WJ, Komuniecki R.

J Neurosci. 2019 Mar 18. pii: 2371-18. doi: 10.1523/JNEUROSCI.2371-18.2019. [Epub ahead of print]

PMID:
30886012
13.

Allergenic ingredients in commercial topical cannabinoid preparations.

Adler BL, DeLeo VA.

J Am Acad Dermatol. 2019 Mar 15. pii: S0190-9622(19)30429-3. doi: 10.1016/j.jaad.2019.03.015. [Epub ahead of print] No abstract available.

PMID:
30885758
14.

The endocannabinoid system in migraine: from bench to pharmacy and back.

Tassorelli C, Greco R, Silberstein SD.

Curr Opin Neurol. 2019 Mar 14. doi: 10.1097/WCO.0000000000000688. [Epub ahead of print]

PMID:
30883435
15.

Modulatory Effects of Cannabinoids on Brain Neurotransmission.

Koby C, Abraham W, Aviv W.

Eur J Neurosci. 2019 Mar 18. doi: 10.1111/ejn.14407. [Epub ahead of print]

PMID:
30882962
16.

Cannabidiol: The Need for More Information About Its Potential Benefits and Side Effects.

Hande K.

Clin J Oncol Nurs. 2019 Apr 1;23(2):131-134. doi: 10.1188/19.CJON.131-134.

PMID:
30880812
17.

Cannabis use disorders may protect against certain disorders of the digestive organs in people with schizophrenia but not in healthy controls.

Olesen JA, Posselt CM, Poulsen CH, Nordentoft M, Hjorthøj C.

Psychol Med. 2019 Mar 18:1-8. doi: 10.1017/S0033291719000370. [Epub ahead of print]

PMID:
30880659
18.

Metformin inhibits both oleic acid-induced and CB1R receptor agonist-induced lipid accumulation in Hep3B cells: The preliminary report.

Szuster-Ciesielska A, Zwolak A, Daniluk J, Kandefer-Szerszeń M.

Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419832714. doi: 10.1177/2058738419832714.

PMID:
30880507
19.

Liprin alfa 2 gene expression is increased by cannabis use and associated with neuropsychological function.

He Y, de Witte LD, Schubart CD, Van Gastel WA, Koeleman BPC, de Jong S, Ophoff RA, Hol EM, Boks MP.

Eur Neuropsychopharmacol. 2019 Mar 14. pii: S0924-977X(19)30192-0. doi: 10.1016/j.euroneuro.2019.03.004. [Epub ahead of print]

PMID:
30879928
20.

Cannabimimetic plants: are they new cannabinoidergic modulators?

Kumar A, Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Memo M, Mastinu A.

Planta. 2019 Mar 15. doi: 10.1007/s00425-019-03138-x. [Epub ahead of print] Review.

PMID:
30877436

Supplemental Content

Loading ...
Support Center